(19)
(11) EP 3 811 927 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.02.2022 Bulletin 2022/08

(45) Mention of the grant of the patent:
17.11.2021 Bulletin 2021/46

(21) Application number: 20162018.4

(22) Date of filing: 10.03.2020
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 38/09(2006.01)
A61P 15/00(2006.01)
 A61K 9/08(2006.01)
A61K 47/12(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0019; A61K 38/09; A61P 15/00; A61K 9/08; A61K 47/12

(54)

A STABLE PARENTERAL DOSAGE FORM OF CETRORELIX ACETATE

STABILE PARENTERALE DOSIERUNGSFORM VON CETRORELIXACETAT

FORME POSOLOGIQUE PARENTÉRALE STABLE D'ACÉTATE DE CÉTRORÉLIX

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 24.10.2019 IN 201921043355

(43) Date of publication of application:
28.04.2021 Bulletin 2021/17

(73) Proprietor: Sun Pharmaceutical Industries Ltd
400063 Mumbai, Maharashtra (IN)

(72) Inventors:
  • JOSHI, Jaydip
    390 012 Baroda (IN)
  • THUMMAR, Rakesh
    390 012 Baroda (IN)
  • AGRAWAL, Sudeep
    390 012 Baroda (IN)
  • BHOWMICK, Subhas Balaram
    390 012 Baroda (IN)
  • YADAV, Arunkumar
    390 012 Baroda (IN)
  • THENNATI, Rajamannar
    390 012 Baroda (IN)

(74) Representative: Harrison IP Limited 
3 Ebor House Millfield Lane
Nether Poppleton, York YO26 6QY
Nether Poppleton, York YO26 6QY (GB)


(56) References cited: : 
US-A1- 2013 303 464
 US-B2- 7 718 599
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).